Abciximab
In clinical developmentAlso known as Reopro, c7E3.
Recent clinical, regulatory, research and industry developments relating to this drug.
Stroke Prevention With Abciximab in Carotid Endarterectomy
Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis
A Randomized Control Trial of Intracoronary Reopro to Improve Coronary Microvascular Function
Eptifibatide Versus Abciximab in Primary PCI for Acute ST Elevation Myocardial Infarction
IntraCoronary Abciximab With the ClearWay Catheter To Improve Outcomes With Lysis
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Intravenous vs. Intracoronary Use of Abciximab
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes1
Journals, researchers & institutions
- Circulation1
- Stroke1
- Adams HP Jr1
- Anderson KM1
- Balog C1
- Barnathan ES1
- Booth JE1
- Cabot CF1
- Califf RM1
- Dávalos A1
- Carver College of Medicine1
- The Cleveland Clinic Foundation1
- RxNorm (U.S. National Library of Medicine) — drug identity
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials